Department of Cardiology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
Department of Electrocardiographic and Cardiac Function, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
Biomed Res Int. 2020 Apr 6;2020:6720481. doi: 10.1155/2020/6720481. eCollection 2020.
Atrial fibrillation (AF) is a common arrhythmia contributing to severe outcomes, including cardiac dysfunction and stroke, and it has drawn great attention around the world. Drug therapies have been available for many years to terminate AF and control heart rate. However, the results from clinical studies on drug therapies have been discouraging. Mounting evidence indicates that radiofrequency catheter ablation (RFCA) is a safe and effective method to maintain sinus rhythm, especially in patients who are drug intolerant or for whom the drugs are ineffective, although it is a technically demanding and complex procedure. Fortunately, a novel application, cryoballoon ablation (CBA), with outstanding characteristics has been widely used. Great outcomes based on CBA have manifested its significant role in the treatment of AF. However, how to improve the safety and efficacy of CBA is a question that has not been well-answered. Would it be helpful to develop a different generation of cryoballoon? Is bonus freezing beneficial, or not? Is it better to prolong freezing time? Dose CBA combined with RFCA bring higher success rates? In this review, we comprehensively summarized useful applications for improving outcomes of CBA in AF patients.
心房颤动（AF）是一种常见的心律失常，可导致严重后果，包括心功能障碍和中风，因此引起了全球的高度关注。多年来，已有多种药物疗法可用于终止 AF 并控制心率。然而，药物治疗的临床研究结果令人沮丧。越来越多的证据表明，射频导管消融（RFCA）是维持窦性心律的一种安全有效的方法，特别是在药物不耐受或药物无效的患者中，尽管它是一种技术要求高且复杂的程序。幸运的是，一种新型应用，冷冻球囊消融（CBA），具有出色的特性，已被广泛应用。基于 CBA 的良好结果表明其在 AF 治疗中的重要作用。然而，如何提高 CBA 的安全性和疗效是一个尚未得到很好回答的问题。开发新一代冷冻球囊是否有帮助？附加冷冻是否有益，还是无益？延长冷冻时间是否更好？CBA 联合 RFCA 的剂量是否会带来更高的成功率？在这篇综述中，我们全面总结了改善 AF 患者 CBA 结果的有用应用。
